These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21122466)

  • 1. Investigation of carbachol and PACAP38 in a human model of migraine.
    Schytz HW
    Dan Med Bull; 2010 Dec; 57(12):B4223. PubMed ID: 21122466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
    Amin FM; Hougaard A; Schytz HW; Asghar MS; Lundholm E; Parvaiz AI; de Koning PJ; Andersen MR; Larsson HB; Fahrenkrug J; Olesen J; Ashina M
    Brain; 2014 Mar; 137(Pt 3):779-94. PubMed ID: 24501094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of genetics on migraine induction triggered by CGRP and PACAP38.
    Guo S
    Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PACAP38 induces migraine-like attacks in patients with migraine without aura.
    Schytz HW; Birk S; Wienecke T; Kruuse C; Olesen J; Ashina M
    Brain; 2009 Jan; 132(Pt 1):16-25. PubMed ID: 19052139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38.
    Baun M; Pedersen MH; Olesen J; Jansen-Olesen I
    Cephalalgia; 2012 Mar; 32(4):337-45. PubMed ID: 22421901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients.
    Guo S; Vollesen AL; Hansen YB; Frandsen E; Andersen MR; Amin FM; Fahrenkrug J; Olesen J; Ashina M
    Cephalalgia; 2017 Feb; 37(2):136-147. PubMed ID: 26994298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
    Rasmussen NB; Deligianni C; Christensen CE; Karlsson WK; Al-Khazali HM; Van de Casteele T; Granhall C; Amin FM; Ashina M
    J Headache Pain; 2023 May; 24(1):60. PubMed ID: 37231350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.
    Vollesen ALH; Snoer A; Chaudhry B; Petersen AS; Hagedorn A; Hoffmann J; Jensen RH; Ashina M
    Cephalalgia; 2020 Nov; 40(13):1474-1488. PubMed ID: 32962406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PACAP38 and PAC
    Rubio-Beltrán E; Correnti E; Deen M; Kamm K; Kelderman T; Papetti L; Vigneri S; MaassenVanDenBrink A; Edvinsson L;
    J Headache Pain; 2018 Aug; 19(1):64. PubMed ID: 30088106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.
    Schytz HW; Holst H; Arendt-Nielsen L; Olesen J; Ashina M
    J Headache Pain; 2010 Aug; 11(4):309-16. PubMed ID: 20454993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
    Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
    Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.
    Rahmann A; Wienecke T; Hansen JM; Fahrenkrug J; Olesen J; Ashina M
    Cephalalgia; 2008 Mar; 28(3):226-36. PubMed ID: 18254893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PACAP38 dose-response pilot study in migraine patients.
    Vollesen AL; Guo S; Ashina M
    Cephalalgia; 2017 Apr; 37(4):391-395. PubMed ID: 27084887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PACAP38 in human models of primary headaches.
    Ashina H; Guo S; Vollesen ALH; Ashina M
    J Headache Pain; 2017 Nov; 18(1):110. PubMed ID: 29453754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
    Vollesen ALH; Amin FM; Ashina M
    Neurotherapeutics; 2018 Apr; 15(2):371-376. PubMed ID: 29464574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.
    Baun M; Hay-Schmidt A; Edvinsson L; Olesen J; Jansen-Olesen I
    Eur J Pharmacol; 2011 Nov; 670(1):186-94. PubMed ID: 21914446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study.
    Amin FM; Hougaard A; Magon S; Asghar MS; Ahmad NN; Rostrup E; Sprenger T; Ashina M
    Neurology; 2016 Jan; 86(2):180-7. PubMed ID: 26674334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine.
    Guo S; Vollesen AL; Hansen RD; Esserlind AL; Amin FM; Christensen AF; Olesen J; Ashina M
    Cephalalgia; 2017 Feb; 37(2):125-135. PubMed ID: 26994299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the H
    Vollesen LH; Guo S; Andersen MR; Ashina M
    Cephalalgia; 2019 Apr; 39(5):597-607. PubMed ID: 30165750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.